Standard of Care and Protecting Every Filter
At a Glance
Children with oligomeganephronia cannot grow new nephrons after birth, so care focuses on protecting the remaining kidney filters. Blood pressure control, selected RAS inhibitors, avoiding kidney-harming medicines, and monitoring CKD complications can help preserve kidney function.
While there is currently no way to grow more filtering units (nephrons) once a child is born, the goal of modern medical care is to protect the ones they have. This strategy, often called nephroprotection, focuses on reducing the workload and stress on the remaining enlarged filters to keep them healthy for as long as possible, as part of comprehensive CKD care [1][2].
Reducing “Overwork” with RAS Inhibitors
A key tool in protecting OMN kidneys is a class of medications called Renin-Angiotensin System (RAS) inhibitors. Not every child needs these, but they are commonly prescribed for clinically significant proteinuria or hypertension. These include ACE inhibitors (like lisinopril or enalapril) and ARBs (like losartan or valsartan) [1].
These medications work by relaxing the blood vessels leading away from the filters. This reduces the “back-pressure” inside the glomeruli, a process called lowering hyperfiltration [2][1]. By lowering this pressure, the medications help:
- Reduce Proteinuria: They help stop protein from leaking into the urine, which is a major source of kidney scarring [3].
- Lower Blood Pressure: They manage the systemic hypertension that often accompanies OMN [1].
- Slow Scarring: They may have anti-inflammatory and anti-fibrotic (anti-scarring) effects that protect kidney tissue over time [1].
Your doctor will likely start these at a low dose and slowly increase them. Note that ACE inhibitors and ARBs should not be combined unless a specialist has a compelling reason. They will monitor your child’s blood for changes in potassium levels or a sudden drop in kidney function (eGFR), which can sometimes happen when starting these drugs. Side effects can include low blood pressure, dizziness, cough, and severe risks during pregnancy [4][5].
Strict Blood Pressure Control
In children with OMN, blood pressure is not just a number; it is a direct measurement of the stress on the kidneys. Current guidelines often target a blood pressure below the 50th percentile for the child’s age, sex, and height, individualized by your nephrologist [6][7]. Do not adjust medications based on a single home reading.
Because clinic visits can be stressful and produce “white coat” readings, doctors often use Ambulatory Blood Pressure Monitoring (ABPM) to assess this target. This involves a wearable cuff that takes readings over 24 hours, including while the child sleeps. This is vital because high blood pressure at night (nocturnal hypertension) is common in kidney disease and can be missed in the office [8][9][10].
Avoiding Kidney “Insults”
Protecting the kidneys also means avoiding substances that can cause sudden injury (nephrotoxicity).
- NSAIDs: Medications like ibuprofen (Advil, Motrin) and naproxen (Aleve) should generally be avoided, though occasional use must be individualized by your clinician. They work by constricting blood flow to the kidneys, which can cause a sudden drop in function [11][12]. Acetaminophen (Tylenol) is typically the preferred alternative for pain or fever [11].
- Be Cautious with Contrast: Certain dyes used in CT scans (iodinated contrast) can be hard on the kidneys. Always inform any medical provider that your child has OMN before imaging; the radiologist must weigh the kidney status and hydration [13][14].
- Supplement Safety: Always check with your nephrologist before starting herbal supplements or high-dose vitamins, as some can interfere with kidney function [14].
Managing CKD Complications
As OMN is a form of chronic kidney disease (CKD), the care team will also focus on several “behind-the-scenes” aspects of your child’s health:
- Nutrition and Growth: Kids with OMN may need extra calories or specific protein adjustments to grow properly. A pediatric renal dietitian is a key part of the care team [15][16].
- Metabolic Acidosis: If the kidneys cannot remove enough acid from the blood, your child may need sodium bicarbonate or sodium citrate supplements to keep their blood chemistry balanced and support bone growth. Never treat this with kitchen baking soda, as the dosing is completely different. [17].
- Bone Health: The kidneys help balance calcium, phosphate, and Vitamin D. Your team will monitor these to prevent bone mineral disease, which can make bones weak or affect growth [18][19].
By managing these factors early, you and your medical team are giving the remaining nephrons the best possible environment to continue their vital work [15][2].
Common questions in this guide
Why are RAS inhibitors used in children with oligomeganephronia?
What blood pressure target is used for a child with oligomeganephronia?
Why might my child need a 24-hour blood pressure monitor?
Can my child take ibuprofen for pain or fever with oligomeganephronia?
How does chronic kidney disease care support my child's growth and bone health?
Get notified when new evidence is published on Oligomeganephronia.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (19)
- 1
Management of Hypertension in CAKUT: Protective Factor for CKD.
Gabriele MM, Koch Nogueira PC
Frontiers in pediatrics 2019; (7()):222 doi:10.3389/fped.2019.00222.
PMID: 31214554 - 2
How to delay the progression of chronic kidney disease: focusing on medications.
Min J
Childhood kidney diseases 2024; (28(2)):51-58 doi:10.3339/ckd.24.006.
PMID: 42779624 - 3
Renin angiotensin aldosterone inhibitors in the treatment of proteinuria in children with congenital anomalies of the kidney and urinary tract: more evidence needed.
Rivetti G, Gizzone P, Di Sessa A, et al.
Expert review of clinical pharmacology 2023; (16(9)):791-798 doi:10.1080/17512433.2023.2247985.
PMID: 37577983 - 4
Hyperkalemia Associated with Angiotensin Converting Enzyme Inhibitor or Angiotensin Receptor Blockers in Chronic Kidney Disease.
Oktaviono YH, Kusumawardhani N
Acta medica Indonesiana 2020; (52(1)):74-79.
PMID: 32291375 - 5
Single, Double and Triple Blockade of RAAS in Alport Syndrome: Different Tools to Freeze the Evolution of the Disease.
Mastrangelo A, Brambilla M, Romano G, et al.
Journal of clinical medicine 2021; (10(21)) doi:10.3390/jcm10214946.
PMID: 34768466 - 6
Hypertension in pediatric patients with chronic kidney disease: management challenges.
Gallibois CM, Jawa NA, Noone DG
International journal of nephrology and renovascular disease 2017; (10()):205-213 doi:10.2147/IJNRD.S100891.
PMID: 28794651 - 7
Intensive compared with less intensive blood pressure control to prevent adverse cardiac remodelling in children with chronic kidney disease (HOT-KID): a parallel-group, open-label, multicentre, randomised, controlled trial.
Sinha MD, Gu H, Douiri A, et al.
The Lancet. Child & adolescent health 2023; (7(1)):26-36 doi:10.1016/S2352-4642(22)00302-9.
PMID: 36442482 - 8
Practical application of ABPM in the pediatric nephrology clinic.
Halbach S
Pediatric nephrology (Berlin, Germany) 2020; (35(11)):2067-2076 doi:10.1007/s00467-019-04361-0.
PMID: 31732802 - 9
[Office and 24-hour ambulatory blood pressure measurements in hypertension assessment in children with chronic kidney disease].
Łątka M, Drożdż T, Kwinta P, et al.
Przeglad lekarski 2016; (73(5)):287-95.
PMID: 29629741 - 10
Prevalence of masked hypertension and its association with left ventricular hypertrophy in children and young adults with chronic kidney disease: a systematic review and meta-analysis.
Goulas I, Evripidou K, Doundoulakis I, et al.
Journal of hypertension 2023; (41(5)):699-707 doi:10.1097/HJH.0000000000003402.
PMID: 36883474 - 11
NSAIDs in CKD: Are They Safe?
Baker M, Perazella MA
American journal of kidney diseases : the official journal of the National Kidney Foundation 2020; (76(4)):546-557 doi:10.1053/j.ajkd.2020.03.023.
PMID: 32479922 - 12
Practical Approach to Detection and Management of Chronic Kidney Disease for the Primary Care Clinician.
Vassalotti JA, Centor R, Turner BJ, et al.
The American journal of medicine 2016; (129(2)):153-162.e7.
PMID: 26391748 - 13
Analysis of the association between emergency dialysis start in patients with end-stage kidney disease and non-steroidal anti-inflammatory drugs, proton-pump inhibitors, and iodinated contrast agents.
Pétureau A, Raffray M, Polard E, et al.
Journal of nephrology 2021; (34(5)):1711-1723 doi:10.1007/s40620-020-00952-5.
PMID: 33877637 - 14
Renal Repercussions of Medications.
Shaddock R, Anderson KV, Beyth R
Primary care 2020; (47(4)):691-702 doi:10.1016/j.pop.2020.08.006.
PMID: 33121637 - 15
Malnutrition management in children with chronic kidney disease.
Corsello A, Trovato CM, Dipasquale V, et al.
Pediatric nephrology (Berlin, Germany) 2025; (40(1)):15-24 doi:10.1007/s00467-024-06436-z.
PMID: 38954039 - 16
Chronic Kidney Disease: Treatment of Comorbidities I: (Nutrition, Growth, Neurocognitive Function, and Mineral Bone Disease).
Kogon AJ, Harshman LA
Current treatment options in pediatrics 2019; (5()):78-92 doi:10.1007/s40746-019-00152-9.
PMID: 31840017 - 17
Chronic Kidney Disease: Role of Diet for a Reduction in the Severity of the Disease.
Naber T, Purohit S
Nutrients 2021; (13(9)) doi:10.3390/nu13093277.
PMID: 34579153 - 18
Assessing bone mineralisation in children with chronic kidney disease: what clinical and research tools are available?
Lalayiannis AD, Crabtree NJ, Fewtrell M, et al.
Pediatric nephrology (Berlin, Germany) 2020; (35(6)):937-957 doi:10.1007/s00467-019-04271-1.
PMID: 31240395 - 19
Diagnosis and management of mineral and bone disorders in infants with CKD: clinical practice points from the ESPN CKD-MBD and Dialysis working groups and the Pediatric Renal Nutrition Taskforce.
Bacchetta J, Schmitt CP, Bakkaloglu SA, et al.
Pediatric nephrology (Berlin, Germany) 2023; (38(9)):3163-3181 doi:10.1007/s00467-022-05825-6.
PMID: 36786859
This page explains kidney-protective care for children with oligomeganephronia for informational purposes only and does not replace medical advice. Your child's pediatric nephrology team should guide medicines, blood pressure targets, and treatment decisions.